ARWR

14.71

12.23% -2.05

Dopo l'orario di chiusura: 15.00 0.29 +1.97%

Arrowhead Pharmaceuticals Inc (ARWR)

Panoramica Notizia Cronologia dei prezzi Catena di opzioni Financials Perché ARWR Giù? Forum Previsione Frazionamento azionario

Precedente Chiudi:

$16.76

Aprire:

$16.96

Volume 24 ore:

6.75M

Relative Volume:

3.80

Capitalizzazione di mercato:

$2.03B

Reddito:

$181.74M

Utile/perdita netta:

$-143.97M

Rapporto P/E:

-10.58

EPS:

-1.39

Flusso di cassa netto:

$9.60M

1 W Prestazione:

-20.96%

1M Prestazione:

-3.98%

6M Prestazione:

-25.56%

1 anno Prestazione:

-48.02%

Intervallo 1D:

$14.32

$17.00

Intervallo di 1 settimana:

$14.32

$19.32

Portata 52W:

$9.57

$29.86

Arrowhead Pharmaceuticals Inc Stock (ARWR) Company Profile

Nome

Arrowhead Pharmaceuticals Inc

Settore

Healthcare (1161)

Industria

Biotechnology (654)

Telefono

626-696-4702

Indirizzo

177 E COLORADO BLVD, PASADENA, CA

Dipendente

609

Cinguettio

@ArrowheadPharma

Prossima data di guadagno

2025-02-10

Ultimi documenti SEC

ARWR's Discussions on Twitter

Confronta ARWR con altri titoli

Azioni	Prezzo	Cap. di mercato	Reddito	Reddito netto	Flusso di cassa	EPS
ARWR Arrowhead Pharmaceuticals Inc	14.71	2.57B	181.74M	-143.97M	9.60M	-1.39
VRTX Vertex Pharmaceuticals Inc	458.49	121.30B	11.10B	-988.90M	-1.26B	-3.92
REGN Regeneron Pharmaceuticals Inc	545.53	61.60B	14.09B	4.50B	2.96B	39.28
ALNY Alnylam Pharmaceuticals Inc	320.52	41.17B	2.35B	-269.70M	-75.39M	-2.09
ARGX Argen X Se Adr	566.14	34.35B	2.58B	1.06B	-1.28B	16.33
ONC Beone Medicines Ltd Adr	291.93	27.29B	3.81B	-644.79M	-669.77M	-6.24

Arrowhead Pharmaceuticals Inc Stock (ARWR) Upgrades & Downgrades

Data	Azione	Analista	Modifica della valutazione
2024-06-05	Iniziato	Goldman	Neutral
2023-12-04	Iniziato	BofA Securities	Buy
2023-09-19	Iniziato	Citigroup	Neutral
2023-07-21	Iniziato	TD Cowen	Outperform
2023-05-12	Downgrade	SVB Securities	Outperform → Market Perform
2023-04-26	Iniziato	SMBC Nikko	Outperform
2023-04-12	Aggiornamento	SVB Securities	Market Perform → Outperform
2023-03-21	Iniziato	Bernstein	Mkt Perform
2022-09-09	Iniziato	Morgan Stanley	Equal-Weight
2022-05-11	Aggiornamento	Robert W. Baird	Neutral → Outperform
2022-01-19	Ripresa	Goldman	Buy
2021-08-06	Reiterato	Chardan Capital Markets	Buy
2021-06-04	Ripresa	Robert W. Baird	Neutral
2021-02-05	Reiterato	H.C. Wainwright	Buy
2020-12-21	Downgrade	Robert W. Baird	Outperform → Neutral
2020-12-16	Iniziato	UBS	Buy
2020-11-19	Iniziato	Citigroup	Buy
2020-05-13	Iniziato	RBC Capital Mkts	Outperform
2020-05-08	Aggiornamento	Oppenheimer	Perform → Outperform
2020-04-15	Aggiornamento	Cantor Fitzgerald	Neutral → Overweight
2020-03-24	Aggiornamento	SVB Leerink	Underperform → Mkt Perform
2020-03-17	Iniziato	Goldman	Neutral
2020-01-21	Iniziato	SVB Leerink	Underperform
2019-12-13	Iniziato	Oppenheimer	Perform
2019-11-29	Reiterato	Chardan Capital Markets	Buy
2019-11-27	Reiterato	B. Riley FBR	Buy
2019-11-25	Aggiornamento	Robert W. Baird	Neutral → Outperform
2019-10-24	Downgrade	Robert W. Baird	Outperform → Neutral
2019-10-22	Reiterato	Chardan Capital Markets	Buy
2019-10-03	Iniziato	Robert W. Baird	Outperform
2018-09-07	Aggiornamento	B. Riley FBR	Neutral → Buy
2018-09-06	Reiterato	Chardan Capital Markets	Buy
2018-08-08	Reiterato	Cantor Fitzgerald	Overweight
2018-07-02	Reiterato	Chardan Capital Markets	Buy

Mostra tutto

Arrowhead Pharmaceuticals Inc Borsa (ARWR) Ultime notizie

08:59 AM

What drives Arrowhead Pharmaceuticals Inc. stock priceFree Stock Market Return Analysis - Autocar Professional

08:59 AM

04:01 AM

Arrowhead Pharmaceuticals to Webcast Fiscal 2025 Third Quarter Results - Yahoo Finance

04:01 AM

01:39 AM

What analysts say about Arrowhead Pharmaceuticals Inc. stockExceptional profit velocity - Autocar Professional

01:39 AM

11:58 AM

Arrowhead hits the skids due to partnership with Sarepta - Seeking Alpha

11:58 AM

10:35 AM

Arrowhead Pharmaceuticals Plummets 9.4%: A Bearish Surprise in Biotech's RNAi Frontier - AInvest

10:35 AM

Jul 20, 2025

Arrowhead Pharmaceuticals Inc. Stock Analysis and ForecastPowerful market insights - Autocar Professional

Jul 20, 2025

Jul 19, 2025

Is Arrowhead Pharmaceuticals Inc. a good long term investmentExceptional growth trajectory - jammulinksnews.com

Jul 19, 2025

Jul 18, 2025

Insiders At Arrowhead Pharmaceuticals Sold US$3.1m In Stock, Alluding To Potential Weakness - simplywall.st

Jul 18, 2025

Jul 10, 2025

Arrowhead Pharmaceuticals Advances Phase 3 Study on Plozasiran for Hypertriglyceridemia - TipRanks

Jul 10, 2025

Jul 09, 2025

Arrowhead Pharmaceuticals (ARWR) Soars 7.64% on Clinical Trial Advances - AInvest

Jul 09, 2025

Arrowhead Pharmaceuticals Advances Phase 3 Study of Zodasiran for Cholesterol Management - TipRanks

Jul 09, 2025

Jul 08, 2025

Arrowhead Pharmaceuticals' Zodasiran: A Pioneering ANGPTL3 Inhibitor for HoFH and Beyond - AInvest

Jul 08, 2025

Arrowhead Pharmaceuticals initiates phase 3 Yosemite study of investigational zodasiran - MarketScreener

Jul 08, 2025

Arrowhead Pharmaceuticals Initiates Phase 3 YOSEMITE Study of Investigational Zodasiran for the Treatment of Homozygous Familial Hypercholesterolemia - Business Wire

Jul 08, 2025

Jun 25, 2025

Hepatitis D Clinical Trials, Companies, Therapeutic Assessment, Therapies, Treatment Algorithm, Pipeline Analysis | Eiger Biopharmaceuticals, Arrowhead Pharmaceuticals, Antios Therapeutics, PharmaEsse - The Globe and Mail

Jun 25, 2025

Jun 23, 2025

Arrowhead Pharmaceuticals Completes Enrollment in SHASTA-3, SHASTA-4, and MUIR-3 Phase 3 Studies of Plozasiran - Business Wire

Jun 23, 2025

Jun 12, 2025

Where are the Opportunities in (ARWR) - news.stocktradersdaily.com

Jun 12, 2025

Homozygous Familial Hypercholesterolemia Market to Reach New Heights in Growth by 2034, DelveInsight Predicts | Arrowhead Pharma, Novartis, Alnylam Pharma, LIB Therapeutics, Amryt Pharma - The Globe and Mail

Jun 12, 2025

GAMMA Investing LLC Increases Stock Position in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) - Defense World

Jun 12, 2025

Cantor Fitzgerald Weighs in on ARWR FY2026 Earnings - Defense World

Jun 12, 2025

Jun 10, 2025

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Receives Average Recommendation of “Moderate Buy” from Analysts - Defense World

Jun 10, 2025

Jun 09, 2025

Arrowhead Pharmaceuticals at Goldman Sachs Conference: Strategic Launch Plans By Investing.com - Investing.com Canada

Jun 09, 2025

Jun 08, 2025

California State Teachers Retirement System Reduces Holdings in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) - Defense World

Jun 08, 2025

Jun 07, 2025

Arrowhead Pharmaceuticals (NASDAQ:ARWR) Upgraded to “Buy” at Wall Street Zen - Defense World

Jun 07, 2025

Jun 05, 2025

Jim Cramer on Arrowhead Pharmaceuticals (ARWR): “It Doesn’t Make Any Money” - Insider Monkey

Jun 05, 2025

Jun 04, 2025

Arrowhead at Jefferies Conference: Strategic Pipeline Insights By Investing.com - Investing.com Canada

Jun 04, 2025

Jim Cramer: Arrowhead Pharmaceuticals Doesn't 'Have The Horses' - Benzinga

Jun 04, 2025

Arrowhead Pharmaceuticals to Participate in June 2025 Investor Conferences - Business Wire

Jun 04, 2025

Jun 02, 2025

Arrowhead (ARWR) Kicks Off Clinical Trial for Obesity Treatment ARO-ALK7 | ARWR Stock News - GuruFocus

Jun 02, 2025